Diretriz atualizada da OMS recomenda condicionalmente o molnupiravir para pacientes com Covid-19 não grave sob alto risco de internação.
8 Mar, 2022 | 16:14hComunicado de imprensa BMJ: WHO recommends antiviral drug for patients with non-severe covid-19 at highest risk of hospital admission – BMJ
Comunicado de imprensa OMS: WHO updates its treatment guidelines to include molnupiravir
Ver diretriz atualizada: A living WHO guideline on drugs for covid-19 – BMJ
Conteúdos relacionados:
Editorial (recém-publicado): Molnupiravir’s authorisation was premature – The BMJ
FDA panel narrowly recommends authorization of first antiviral pill to treat COVID.
8 lingering questions about the new Covid pills from Merck and Pfizer.
The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.
Merck to allow other nations to produce new COVID-19 antiviral.
Video: Merck’s Covid pill could transform treatment. Here’s how it works.
How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.
What we know — and don’t know — about Merck’s new Covid-19 pill.
Merck’s Covid-19 pill is great news but may not be a game-changer.